Randomized, placebo-controlled trial of injectable naltrexone and monthly injectable buprenorphine for cocaine use disorder (CTN-0109). August 15, 2024 to march 31, 2026. N01DA-22-2253. Task order no.…
Ended Awarded Last action
- Contract number
- 75N95024F00006
- Awardee
-
The Emmes Company, LLC UEI NBQCBJ6FXBU4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $525,738
Award facts
- Opportunity
-
- 75N95024F00006 Solicitation number
- Contract value 100% obligated
- $525,738.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- North Bethesda, MD 20852, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute on Drug Abuse (NIDA) awarded a $525,738.00 cost-plus-fixed-fee delivery order contract to The Emmes Company LLC, a for-profit limited liability company, to conduct a randomized, placebo-controlled trial of injectable naltrexone and monthly injectable buprenorphine for the treatment of cocaine use disorder. The contract runs from August 15, 2024 to March 31, 2026 and is not set aside for any specific business type. The Emmes Company LLC is a global clinical research organization that has secured multiple prime and subcontract awards from NIDA and other NIH institutes to provide a range of services including data management, statistical analysis, and operational support for clinical trials and research programs related to public health.
Description
Randomized, placebo-controlled trial of injectable naltrexone and monthly injectable buprenorphine for cocaine use disorder (CTN-0109). August 15, 2024 to march 31, 2026. N01DA-22-2253. Task order no. 75N95024F00006 (TO22).
Quick answers
Who was awarded contract 75N95024F00006?
75N95024F00006 was awarded to The Emmes Company, LLC by National Institute on Drug Abuse (National Institutes of Health) on August 15, 2024.
How much is contract 75N95024F00006 worth?
The government has obligated $525,738 on 75N95024F00006.
Is contract 75N95024F00006 an order under another contract?
Yes. 75N95024F00006 is a delivery order under 75N95022D00017, an indefinite delivery contract.
Was contract 75N95024F00006 competed?
The extent of competition for 75N95024F00006 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award